In early March 2026, the FDA confirmed it had sent “thousands” of letters to telehealth and pharmaceutical companies since September 2025 regarding misleading advertising of compounded GLP-1 products. A single batch in March 2026 hit more than 30 companies at once.
This wasn’t a quiet regulatory nudge. It was the most aggressive enforcement action the FDA has taken against the compounded GLP-1 industry. And for patients relying on these providers, understanding what the violations actually were — and which companies got caught — is essential for protecting your health and your wallet.
The Two Rounds of Warning Letters
The FDA’s enforcement came in distinct waves. The first round, beginning in September 2025, targeted companies making specific advertising claims. The second, larger round in March 2026 expanded the scope and included more aggressive language about potential legal action.
According to the FDA’s March 3, 2026 public release, the warning letters focused on two main categories of violations.
Violation Category 1: Misleading Advertising Claims
The FDA cited companies for advertising practices that implied their compounded products were equivalent to or interchangeable with FDA-approved drugs. Specific violations included:
Claiming the same active ingredient. Advertisements stating that a compounded product contains “the same active ingredient as Wegovy” or “the same semaglutide in Ozempic” were flagged. The FDA’s position is that compounded drugs are not FDA-approved and cannot claim equivalence to products that are.
Using the word “generic.” Multiple companies marketed compounded semaglutide as a “generic” or “generic alternative.” There are no FDA-approved generic versions of semaglutide. Compounded products are not generics. The FDA was explicit: “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”
Implying identical outcomes. Companies that suggested patients would achieve the same results as clinical trials of FDA-approved drugs were also cited. Since compounded products have not been through FDA review, efficacy claims based on branded drug trial data are considered misleading.
Falsely implying they compound the drug. Some telehealth platforms that purchase compounded medications from third-party pharmacies were marketing as though they performed the compounding themselves. This misrepresentation is both a branding violation and a supply chain transparency issue.
Violation Category 2: Product Safety and Legality Concerns
Beyond advertising, the FDA also flagged companies for fundamental product safety issues:
Using unapproved salt forms. Some compounded products contained semaglutide sodium or other salt forms that differ chemically from the FDA-approved semaglutide base. The FDA considers these unapproved new drugs rather than legitimate compounded versions.
Continuing to compound after shortage resolution. With the semaglutide shortage resolved in February 2025, the legal basis for compounding copies of commercially available drugs ended. Companies that continued large-scale production were operating outside the law.
Cold-chain failures. The FDA highlighted concerns about injectable compounded GLP-1s being shipped without adequate temperature control. Products arriving warm or with insufficient ice packs may have degraded, creating both efficacy and safety risks.
The Counterfeit Problem
The FDA also identified fraudulent compounded products entering the market with fake pharmacy names, nonexistent addresses, and labels from licensed pharmacies that did not actually compound the products. At least one adverse event was reported from such a product. This is a separate issue from the advertising violations — it’s outright fraud, and it puts patients at serious risk.
How to Tell If Your Provider Was Flagged
The FDA does not always publish the names of warning letter recipients immediately. However, you can check several things:
Search the FDA warning letter database. The FDA publishes warning letters on its website, typically within a few weeks of issuance. You can search by company name at FDA.gov/warning-letters.
Check your provider’s website for language changes. Companies that received warning letters often quietly update their marketing. If your provider used to say “same active ingredient as Ozempic” or “generic semaglutide” and those phrases have disappeared, they may have been flagged.
Ask directly. You have every right to ask your telehealth provider whether they have received any FDA warning letters or enforcement communications. A transparent provider will answer honestly.
Red Flags: When to Walk Away from a Provider
Based on the violations the FDA cited, here are the warning signs that a GLP-1 telehealth provider may not be operating within the rules:
Red Flag Checklist
• They call their product “generic semaglutide” or “generic Ozempic”
• They claim their compounded product is “the same as” or “identical to” Wegovy, Ozempic, or Zepbound
• They don’t require a medical evaluation before prescribing
• They can’t tell you which pharmacy compounds their medications
• They ship injectable medications without cold-chain packaging
• They sell products labeled “for research use only” with human dosing instructions
• They don’t have follow-up appointments or ongoing monitoring
• Their pricing seems impossibly low (below $100/month for injectables)
Green Flags: Signs Your Provider Is Doing It Right
Legitimate GLP-1 telehealth providers share these characteristics:
Comprehensive medical intake. They ask about your medical history, current medications, allergies, and health goals before prescribing anything. The consultation feels like a real medical appointment, not an online checkout.
Licensed prescribers. Your prescription comes from a physician, nurse practitioner, or physician assistant licensed in your state. You can verify their license through your state’s medical board.
Transparent pharmacy sourcing. They can tell you exactly which pharmacy compounds their medications, and that pharmacy is state-licensed and ideally PCAB-accredited or LegitScript-certified.
Honest marketing language. They do not claim to sell “generic” semaglutide or say their products are “the same as” FDA-approved drugs. They are transparent that compounded products are not FDA-approved.
Proper shipping. Injectable medications arrive with adequate cold-chain packaging and clear storage instructions.
Follow-up care. They schedule regular follow-up appointments and monitor your progress, side effects, and overall health.
What Happens Next
The FDA’s March 2026 enforcement round is likely not the last. Commissioner Makary has signaled that the agency intends to continue using “all available compliance and enforcement tools.” Companies that don’t respond to warning letters may face seizure of products or injunction orders.
For patients, this enforcement is actually good news. It’s clearing out bad actors and making the remaining market safer. The companies that survive this shakeout are the ones that were doing things right all along — providing patient-specific care through licensed pharmacies with proper medical oversight.
If you’re concerned about your current provider, now is the time to evaluate your options. The GLP-1 landscape is expanding with new oral medications, Medicare coverage starting this summer, and falling branded prices. You have more legitimate choices than ever.